The purpose of this research study is to determine whether the combination of UDCA and ATRA
taken for 3 months will improve laboratory tests of liver and bile duct inflammation in
patients with Primary Sclerosing Cholangitis (PSC). Our hypothesis is that a combination of
these medications will improve the liver inflammatory tests in these patients, specifically a
reduction in alkaline phosphatase (AP) by at least 30%.